Real-Time Immunoassays: Quantitative, Fast (10min to result), Simple (one step) using Disposables

Products, services, technology

Elionova's products consist of an instrument using photon counting, disposables (ready-to-use assays or enabling own assays), as well as services to develop custom assays.

Cooperation possibilities

Elionova's technology (ElioDX™) enables rapid immunoassays. We collaborate with immunoreagent and assay producers to quickly expand the available pipeline. Additionally, we develop custom assays for proprietary use, which may also be sold to others, benefiting the original customer.

Some insights

    Elionova's technology accelerates R&D, driving faster innovation. Additionally, we decentralize quantitative immunoassays, enabling precision diagnostics at the point of care, applicable also in developing countries.

    By accelerating R&D and decentralizing quantitative diagnostics, we empower scientists, healthcare professionals, and communities worldwide with faster, more accessible, and lab-grade accurate solutions to improve lives, making high-quality diagnostics available anytime, anywhere

    The biotech industry is driven by visionaries like Katalin Karikó and Drew Weissman, whose mRNA breakthroughs revolutionized vaccines, and J. Doudna, who pioneered CRISPR gene editing. Their relentless innovation inspires us to push boundaries, accelerate discovery, and make a lasting global impact.

    Elionova's core strength lies in its multidisciplinary team of experts, combining deep scientific knowledge, technological innovation, and a passion for transforming diagnostics. Our collaborative approach, agility, and commitment to excellence drive groundbreaking solutions that accelerate R&D.

    At Elionova they work very hard, always pushing boundaries and finding solutions where others see challenges. Their commitment to making diagnostics faster and more accessible is something truly special.

    The Swiss biotech ecosystem provides invaluable support to Elionova, fostering innovation through world-class research institutions, funding opportunities, and a strong network of industry leaders. Switzerland’s commitment to cutting-edge life sciences enables global impact for its biotech SMEs.

    As our technology is designed for broad adoption in research and diagnostic labs, we actively seek to connect with key stakeholders building strong partnerships and collaborations. Our goal is to accelerate the widespread distribution of our technology, ensuring it reaches who can benefit the most.

Location
Additional address info
  • Halle Bleue
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    1-9

You may also be interested in